20 October 2017 Register to receive our free newsletter by email each week
Advanced Search
View Printable Version
Universities and big pharma embrace early-phase deals

Engineering new pharmaceuticals is risky, achingly slow and astronomically expensive. In search of better ways to defray those costs and speed the path to success, Chicago's elite research universities are partnering with the major pharmaceutical companies, ushering in a new era of early-phase collaboration, writes Brigid Sweeney for Crain’s Chicago Business.

In the past, places like the University of Chicago have been better known for their theoretical contributions to science, while pharma has been focused on profit-driven applied research. But the scope of deals is widening as both sides face increasing pressure.

Public funding for academic research has declined over the past decade, with more cuts likely on the horizon under President Donald Trump, while private companies are facing shrinking R&D budgets and drying drug pipelines. Open-ended, early-stage partnerships are more complicated and riskier than late-stage sure bets – but the payoff is potentially huge.
Full report on the Crain’s Chicago Business site
Receive UWN's free weekly e-newsletters

Email address *
First name *
Last name *
Post code / Zip code *
Country *
Organisation / institution *
Job title *
Please send me UWN’s Global Edition      Africa Edition     Both
I receive my email on my mobile phone
I have read the Terms & Conditions *